中文 | English
Return
Total: 142 , 1/15
Show Home Prev Next End page: GO
MeSH:(Capecitabine*)

5.Hand-foot Syndrome Due to Capecitabine.

Chong Won CHOI ; Chang Hun HUH

Korean Journal of Dermatology 2005;43(7):965-968

6.XELOX ± Bevacizumab compared to FOLFOX4 ± Bevacizumab in first line metastatic colorectal cancer in a non-reimbursed health care system: A cost analysis.

Tan Jerry Y. ; Yacat Andrew A ; Sacdalan Dennis L.

Acta Medica Philippina 2015;49(2):64-67

7.Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy.

Jina YUN ; Kyoung Mee KIM ; Seung Tae KIM ; Jung Hoon KIM ; Jung A KIM ; Jee Hyun KONG ; Soo Hyeon LEE ; Young Woong WON ; Jong Mu SUN ; Jeeyun LEE ; Se Hoon PARK ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Won Ki KANG

Cancer Research and Treatment 2010;42(2):101-106

8.Overview of Radiation Therapy for Treating Rectal Cancer.

Bong Hyeon KYE ; Hyeon Min CHO

Annals of Coloproctology 2014;30(4):165-174

9.Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer.

Chi Hwan CHOI ; Won Dong KIM ; Sang Jeon LEE ; Woo Yoon PARK

Radiation Oncology Journal 2012;30(3):99-107

10.Hand-foot Syndrome Following Capecitabine (Xeloda(R)) Monotherapy for Colorectal Cancer.

Soon Do PARK ; Kil Yeon LEE ; Sun Jin PARK ; Suk Hwan LEE ; Sang Mok LEE

Journal of the Korean Society of Coloproctology 2009;25(4):227-233

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 142 , 1/15 Show Home Prev Next End page: GO